US OptionsDetailed Quotes
CTXR240816P1500
- 0.72
- 0.000.00%
15min DelayClose Aug 2 16:00 ET
0.00High0.00Low
0.72Open0.72Pre Close0 Volume44 Open Interest1.50Strike Price0.00Turnover396.89%IV13.91%PremiumAug 16, 2024Expiry Date0.59Intrinsic Value100Multiplier13DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.6122Delta0.5593Gamma1.26Leverage Ratio-0.0099Theta-0.0004Rho-0.77Eff Leverage0.0007Vega
Citius Pharmaceuticals Stock Discussion
Sign in to post a comment
So ive been asked by quite a few people that are newer traders! And because of being where we all have been. They are learning charts and where to enter and exit on momentum / day trades. But having a bit of trouble. Again as we all did and at times still do. Most know that because i cant know others risk tolerance. Or the type of trade they are doing? That i do not give buy / sell advice. But i was asked could i give some swing trade ideas, so they could have a chance to ...
25
4
$Citius Pharmaceuticals(CTXR.US$
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunotherapy fo...
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunotherapy fo...
2
$TenX Keane Acquisition(TENK.US$ Well here we go again! The marger vote to complete business with $Citius Pharmaceuticals(CTXR.US$ Is scheduled for August 2, 2024 at 9:30AM! But as happens with most SPAC’s it could be delayed again? ( as you see in this chat when the votes started if you scroll down ) They are running out of extensions though. So if it gets delayed again? They will be down to to 2 more 30 day extensions! That make the ve...
8
17
$Citius Pharmaceuticals(CTXR.US$
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunother...
Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunother...
2
$Citius Pharmaceuticals(CTXR.US$ I forgot to include this in my July 10th BOLO post! But the vote on TENKU merger is coming! As of now the vote is scheduled for 8/2/2024. Also the company has been busy preparing to commercially launch LYMPHIR if the recieve FDA approval! I will post again that PDUFA Date is 8/13/2024!
7
$Citius Pharmaceuticals(CTXR.US$
Bloodstream Infections - From Threats to Solutions
Investorideas.com published the second part of a series on blood infections treatment, featuring Citius Pharmaceuticals (NASDAQ: CTXR). Citius has made significant advances in its late-stage product candidates, particularly Mino-Lok® for catheter-related bloodstream infections (CRBSIs). The Phase 3 trial of Mino-Lok® showed positive topline results, meeting primary and secondary endpoints with statistical si...
Bloodstream Infections - From Threats to Solutions
Investorideas.com published the second part of a series on blood infections treatment, featuring Citius Pharmaceuticals (NASDAQ: CTXR). Citius has made significant advances in its late-stage product candidates, particularly Mino-Lok® for catheter-related bloodstream infections (CRBSIs). The Phase 3 trial of Mino-Lok® showed positive topline results, meeting primary and secondary endpoints with statistical si...
1
$Citius Pharmaceuticals(CTXR.US$
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Benzinga· May 31 13:061min
Citius Pharmaceuticals (CTXR.US)
0.746
+10.29%
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.
Disclaimer: This content is for inform
HC Wainwright & Co. Reiterates Buy on Citius Pharma, Maintains $4 Price Target
Benzinga· May 31 13:061min
Citius Pharmaceuticals (CTXR.US)
0.746
+10.29%
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price target.
Disclaimer: This content is for inform
1
No comment yet
Jenna Ragan : RIGL!! RIGL!!![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Jenna Ragan : Hehehe! Yes ma’am pretty lady! I just knew that one would get you attention! Hehehe. Thanks for the smile you just gave me! Hehehe![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Jenna Ragan Trytosaveabit OP : You are very welcome![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Seraphicall : CMMB yes.
but you have these many holdings?